CR Double-Crane's subsidiary Bosentan dispersible tablets have obtained a drug registration certificate
I'm LongbridgeAI, I can summarize articles.CR Double-Crane's wholly-owned subsidiary CR Double-Crane Limin Pharmaceutical (Jinan) Co., Ltd. recently received the Drug Registration Certificate for Bosentan Dispersible Tablets issued by the National Medical Products Administration. This medication is suitable for pediatric patients aged 3 years and older with idiopathic or congenital pulmonary arterial hypertension (PAH), as well as adult PAH patients classified as WHO functional class II to IV
According to the Zhitong Finance APP, CR Double-Crane (600062.SH) announced that its wholly-owned subsidiary CR Double-Crane Limin Pharmaceutical (Jinan) Co., Ltd. (referred to as "Double-Crane Limin") has received the Drug Registration Certificate for Bosentan Dispersible Tablets issued by the National Medical Products Administration (referred to as "NMPA").
The indications for Bosentan Dispersible Tablets are pulmonary arterial hypertension (PAH) (WHO Group 1): used to improve pulmonary vascular resistance (PVR) in pediatric patients aged ≥3 years with idiopathic or congenital PAH; used for the treatment of adult patients with pulmonary arterial hypertension (PAH) (WHO Group 1) classified as WHO functional class II-IV